These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 37068712

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.
    Laidlaw TM, Cahill KN, Cardet JC, Murphy K, Cui J, Dioneda B, Kothari P, Raby BA, Israel E, Boyce JA.
    J Allergy Clin Immunol; 2019 Jan; 143(1):316-324.e7. PubMed ID: 29890239
    [Abstract] [Full Text] [Related]

  • 3. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
    Buchheit KM, Cahill KN, Katz HR, Murphy KC, Feng C, Lee-Sarwar K, Lai J, Bhattacharyya N, Israel E, Boyce JA, Laidlaw TM.
    J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.
    Cahill KN, Bensko JC, Boyce JA, Laidlaw TM.
    J Allergy Clin Immunol; 2015 Jan; 135(1):245-52. PubMed ID: 25218285
    [Abstract] [Full Text] [Related]

  • 6. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
    Buchheit KM, Lewis E, Gakpo D, Hacker J, Sohail A, Taliaferro F, Berreondo Giron E, Asare C, Vukovic M, Bensko JC, Dwyer DF, Shalek AK, Ordovas-Montanes J, Laidlaw TM.
    J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
    [Abstract] [Full Text] [Related]

  • 7. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.
    Machado-Carvalho L, Martín M, Torres R, Gabasa M, Alobid I, Mullol J, Pujols L, Roca-Ferrer J, Picado C.
    J Allergy Clin Immunol; 2016 Jan; 137(1):99-107.e7. PubMed ID: 26560040
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease.
    Buchheit KM, Sohail A, Hacker J, Maurer R, Gakpo D, Bensko JC, Taliaferro F, Ordovas-Montanes J, Laidlaw TM.
    J Allergy Clin Immunol; 2022 Aug; 150(2):415-424. PubMed ID: 35460728
    [Abstract] [Full Text] [Related]

  • 10. Systemic expression of inflammatory mediators in patients with chronic rhinosinusitis and nasal polyps with and without Aspirin Exacerbated Respiratory Disease.
    Pezato R, Świerczyńska-Krępa M, Niżankowska-Mogilnicka E, Holtappels G, De Ruyck N, Sanak M, Derycke L, Van Crombruggen K, Bachert C, Pérez-Novo CA.
    Cytokine; 2016 Jan; 77():157-67. PubMed ID: 26615369
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: A hypothesis.
    Picado C, Mullol J, Roca-Ferrer J.
    J Allergy Clin Immunol; 2023 Feb; 151(2):310-313. PubMed ID: 36126795
    [Abstract] [Full Text] [Related]

  • 13. Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes.
    Liu T, Laidlaw TM, Katz HR, Boyce JA.
    Proc Natl Acad Sci U S A; 2013 Oct 15; 110(42):16987-92. PubMed ID: 24085850
    [Abstract] [Full Text] [Related]

  • 14. Levels of eicosanoids in nasal secretions associated with nasal polyp severity in chronic rhinosinusitis.
    Nordström A, Jangard M, Svedberg M, Ryott M, Kumlin M.
    Prostaglandins Leukot Essent Fatty Acids; 2022 Sep 15; 184():102474. PubMed ID: 35917595
    [Abstract] [Full Text] [Related]

  • 15. Mast Cells in Aspirin-Exacerbated Respiratory Disease.
    Abud EM, White AA.
    Curr Allergy Asthma Rep; 2024 Feb 15; 24(2):73-80. PubMed ID: 38217825
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.
    Cahill KN, Raby BA, Zhou X, Guo F, Thibault D, Baccarelli A, Byun HM, Bhattacharyya N, Steinke JW, Boyce JA, Laidlaw TM.
    Am J Respir Cell Mol Biol; 2016 Jan 15; 54(1):34-40. PubMed ID: 26051534
    [Abstract] [Full Text] [Related]

  • 18. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial.
    Schneider TR, Johns CB, Palumbo ML, Murphy KC, Cahill KN, Laidlaw TM.
    J Allergy Clin Immunol Pract; 2018 Jan 15; 6(3):825-831. PubMed ID: 29133219
    [Abstract] [Full Text] [Related]

  • 19. Aspirin provocation increases 8-iso-PGE2 in exhaled breath condensate of aspirin-hypersensitive asthmatics.
    Mastalerz L, Januszek R, Kaszuba M, Wójcik K, Celejewska-Wójcik N, Gielicz A, Plutecka H, Oleś K, Stręk P, Sanak M.
    Prostaglandins Other Lipid Mediat; 2015 Sep 15; 121(Pt B):163-9. PubMed ID: 26209241
    [Abstract] [Full Text] [Related]

  • 20. Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.
    Mitsui C, Kajiwara K, Hayashi H, Ito J, Mita H, Ono E, Higashi N, Fukutomi Y, Sekiya K, Tsuburai T, Akiyama K, Yamamoto K, Taniguchi M.
    J Allergy Clin Immunol; 2016 Feb 15; 137(2):400-11. PubMed ID: 26194538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.